Benchmark analyst Robert Wasserman reiterates OmniAb (NASDAQ:OABI) with a Buy and maintains $8 price target.

RBC Capital analyst Conor McNamara reiterates OmniAb (NASDAQ:OABI) with a Outperform and maintains $7 price target.

HC Wainwright & Co. analyst Joseph Pantginis reiterates OmniAb (NASDAQ:OABI) with a Buy and maintains $11 price target.

2024 Financial GuidanceOmniAb now expects total operating expenses in 2024 to be slightly less than total operating expenses in...

OmniAb (NASDAQ:OABI) reported quarterly losses of $(0.13) per share which beat the analyst consensus estimate of $(0.17) by 23....

Engineered chickens producing single domain antibodies (sdAbs) provided the scientific foundation for OmnidAb™, the Company'...

Technical synergies between xPloration, OmniFlic®, OmniClic® and OmniDeep®enable new bispecific antibody discovery workflows fo...

Benchmark analyst Robert Wasserman reiterates OmniAb (NASDAQ:OABI) with a Buy and maintains $8 price target.

OmniAb (NASDAQ:OABI) reported quarterly losses of $(0.19) per share which missed the analyst consensus estimate of $(0.16) by 1...